Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan.
Chi-Yi ChenChung-Feng HuangPin-Nan ChengKuo-Chih TsengChing-Chu LoHsing-Tao KuoYi-Hsiang HuangChi-Ming TaiCheng-Yuan PengMing-Jong BairChien-Hung ChenMing-Lun YehChih-Lang LinYung-Chang LinPei-Lun LeeLee-Won ChongChao-Hung HungJee-Fu HuangChi-Chieh YangJui-Ting HuChih-Wen LinChun-Ting ChenChia-Chi WangWei-Wen SuTsai-Yuan HsiehChih-Lin LinWei-Lun TsaiTzong-Hsi LeeGuei-Ying ChenSzu-Jen WangChun-Chao ChangLein-Ray MoSheng-Shun YangWen-Chih WuChia-Sheng HuangChou-Kwok HsiungChien-Neng KaoPei-Chien TsaiChen-Hua LiuMei-Hsuan LeeChun-Jen LiuChia-Yen DaiJia-Horng KaoWan-Long ChuangHan-Chieh LinMing-Lung YuPublished in: Liver international : official journal of the International Association for the Study of the Liver (2021)
DAAs are highly effective in treating Taiwanese HCV patients in the real-world setting. Maintaining DAA adherence and selecting highly efficacious regimens are keys to ensure treatment success.
Keyphrases
- hepatitis c virus
- end stage renal disease
- human immunodeficiency virus
- ejection fraction
- newly diagnosed
- chronic kidney disease
- type diabetes
- randomized controlled trial
- clinical trial
- peritoneal dialysis
- study protocol
- adipose tissue
- insulin resistance
- cross sectional
- patient reported outcomes
- smoking cessation
- glycemic control
- replacement therapy
- patient reported
- double blind